References
- Chaiteerakij R, Pan-Ngum W, Poovorawan K, Soonthornworasiri N, Treeprasertsuk S, Phaosawasdi K. Characteristics and outcomes of cholangiocarcinoma by region in Thailand: a nationwide study. World J Gastroenterol. 2017; 23:7160–7.
- Razumilava N, Gores GJ. Cholangiocarcinoma. Lancet. 2014; 383:2168–79.
- Kamsa-ard S, Kamsa-ard S, Luvira V, Suwanrungruang K, Vatanasapt P, Wiangnon S. Risk factors for cholangiocarcinoma in Thailand: a systematic review and meta-analysis. Asian Pac J Cancer Prev. 2018; 19:605–14.
- Songserm N, Woradet S, Sripa B, Ali A. Sustainable prevention of cholangiocarcinoma through community participation in a high-incidence area in Thailand. Asian Pac J Cancer Prev. 2020; 21:777–82.
- Jongsuksuntigul P, Imsomboon T. Epidemiology of opisthorchiasis and national control program in Thailand. Southeast Asian J Trop Med Public Health. 1998; 29:327–32.
- Tabibian JH, Ali AH, Lindor KD. Primary sclerosing cholangitis, part 1: epidemiology, etiopathogenesis, clinical features, and treatment. Gastroenterol Hepatol (N Y). 2018; 14:293–304.
- Kamsa-Ard S, Luvira V, Suwanrungruang K, Kamsa-Ard S, Luvira V, Santong C, et al. Cholangiocarcinoma trends, incidence, and relative survival in Khon Kaen, Thailand from 1989 through 2013: a population-based cancer registry study. J Epidemiol. 2020; 30:108–9.
- Pinlaor P, Pongsamart P, Hongsrichan N, Sangka A, Srilunchang T, Mairiang E, et al. Specific serum IgG, but not IgA, antibody against purified Opisthorchis viverrini antigen associated with hepatobiliary disease and cholangiocarcinoma. Parasitol Int. 2012; 61:212–6.
- Rizvi SI, Gores GJ. Pathogenesis, diagnosis, and management of cholangiocarcinoma. Gastroenterology. 2013; 145:1215–29.
- Blechacz B. Cholangiocarcinoma: current knowledge and new developments. Gut Liver. 2017; 11:13–26.
- Tyson GL, El-Serag HB. Risk factors for cholangiocarcinoma. Hepatology. 2011; 54:173–84.
- Xia J, Jiang SC, Peng HJ. Association between liver fluke infection and hepatobiliary pathological changes: a systematic review and meta-analysis. PLoS One. 2015; 10:e0132673. doi: 10.1371/journal.pone.0132673
- Honjo S, Srivatanakul P, Sriplung H, Kikukawa H, Hanai S, Uchida K, et al. Genetic and environmental determinants of risk for cholangiocarcinoma via Opisthorchis viverrini in a densely infested area in Nakhon Phanom, northeast Thailand. Int J Cancer. 2005; 117:854–60.
- Steele JA, Richter CH, Echaubard P, Saenna P, Stout V, Sithithaworn P, Wilcox BA. Thinking beyond Opisthorchis viverrini for risk of cholangiocarcinoma in the lower Mekong region: a systematic review and meta-analysis. Infect Dis Poverty. 2018; 7:44. doi: 10.1186/s40249-018-0434-3
- Songserm N, Promthet S, Sithithaworn P, Pientong C, Ekalaksananan T, Chopjitt P, Parkin DM. MTHFR polymorphisms and Opisthorchis viverrini infection: a relationship with increased susceptibility to cholangiocarcinoma in Thailand. Asian Pac J Cancer Prev. 2011; 12:1341–5.
- Xiong J, Yin Z, Xu W, Shen Z, Li Y, Lu X. Alcoholic liver disease and risk of cholangiocarcinoma: a systematic review and meta-analysis. Onco Targets Ther. 2018; 11:8211–9.
- Shaib YH, El-Serag HB, Nooka AK, Thomas M, Brown TD, Patt YZ, Hassan MM. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: a hospital-based case-control study. Am J Gastroenterol. 2007; 102:1016–21.
- Songserm N, Promthet S, Pientong C, Ekalaksananan T, Chopjitt P, Wiangnon S. Gene-environment interaction involved in cholangiocarcinoma in the Thai population: polymorphisms of DNA repair genes, smoking and use of alcohol. BMJ Open. 2014; 4:e005447. doi: 10.1136/bmjopen-2014-005447
- Kirstein MM, Vogel A. Epidemiology and risk factors of cholangiocarcinoma. Visc Med. 2016; 32:395–400.
- Mitacek EJ, Brunnemann KD, Hoffmann D, Limsila T, Suttajit M, Martin N, Caplan LS. Volatile nitrosamines and tobacco-specific nitrosamines in the smoke of Thai cigarettes: a risk factor for lung cancer and a suspected risk factor for liver cancer in Thailand. Carcinogenesis. 1999; 20:133–7.
- Kim HJ, Kim JS, Joo MK, Lee BJ, Kim JH, Yeon JE, et al. Hepatolithiasis and intrahepatic cholangiocarcinoma: a review. World J Gastroenterol. 2015; 21:13418–31.
- He XD, Wang L, Liu W, Liu Q, Qu Q, Li BL, Hong T. The risk of carcinogenesis in congenital choledochal cyst patients: an analysis of 214 cases. Ann Hepatol. 2014; 13:819–26.
- Banales JM, Cardinale V, Carpino G, Marzioni M, Andersen JB, Invernizzi P, et al. Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). Nat Rev Gastroenterol Hepatol. 2016; 13:261–80.
- Clements O, Eliahoo J, Kim JU, Taylor-Robinson SD, Khan SA. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: a systematic review and meta-analysis. J Hepatol. 2020; 72:95–103.
- Petrick JL, Thistle JE, Zeleniuch-Jacquotte A, Zhang X, Wactawski-Wende J, Van Dyke AL, et al. Body mass index, diabetes and intrahepatic cholangiocarcinoma risk: the liver cancer pooling project and meta-analysis. Am J Gastroenterol. 2018; 113: 1494–505.
- Li JS, Han TJ, Jing N, Li L, Zhang XH, Ma FZ, Liu JY. Obesity and the risk of cholangiocarcinoma: a meta-analysis. Tumour Biol. 2014; 35:6831–8.